227 related articles for article (PubMed ID: 9338524)
1. Glucagon-like peptide-1 reduces hepatic glucose production indirectly through insulin and glucagon in humans.
Larsson H; Holst JJ; Ahrén B
Acta Physiol Scand; 1997 Aug; 160(4):413-22. PubMed ID: 9338524
[TBL] [Abstract][Full Text] [Related]
2. Lack of effect of exendin-4 and glucagon-like peptide-1-(7,36)-amide on insulin action in non-diabetic humans.
Vella A; Shah P; Reed AS; Adkins AS; Basu R; Rizza RA
Diabetologia; 2002 Oct; 45(10):1410-5. PubMed ID: 12378382
[TBL] [Abstract][Full Text] [Related]
3. Suppression of glucose production by GLP-1 independent of islet hormones: a novel extrapancreatic effect.
Prigeon RL; Quddusi S; Paty B; D'Alessio DA
Am J Physiol Endocrinol Metab; 2003 Oct; 285(4):E701-7. PubMed ID: 12773303
[TBL] [Abstract][Full Text] [Related]
4. Effect of ketone bodies on glucose production and utilization in the miniature pig.
Müller MJ; Paschen U; Seitz HJ
J Clin Invest; 1984 Jul; 74(1):249-61. PubMed ID: 6376544
[TBL] [Abstract][Full Text] [Related]
5. Glucose metabolism during exercise in man: the role of insulin in the regulation of glucose utilization.
Lavoie C; Ducros F; Bourque J; Langelier H; Chiasson JL
Can J Physiol Pharmacol; 1997 Jan; 75(1):36-43. PubMed ID: 9101063
[TBL] [Abstract][Full Text] [Related]
6. No effect of beta-adrenergic blockade on hypoglycaemic effect of glucagon-like peptide-1 (GLP-1) in normal subjects.
Toft-Nielsen M; Hvidberg A; Hilsted J; Dige-Petersen H; Holst JJ
Diabet Med; 1996 Jun; 13(6):544-8. PubMed ID: 8799658
[TBL] [Abstract][Full Text] [Related]
7. The role of insulin and glucagon in the regulation of basal glucose production in the postabsorptive dog.
Cherrington AD; Chiasson JL; Liljenquist JE; Jennings AS; Keller U; Lacy WW
J Clin Invest; 1976 Dec; 58(6):1407-18. PubMed ID: 993351
[TBL] [Abstract][Full Text] [Related]
8. The effect of glucagon-like peptide I (GLP-I) on glucose elimination in healthy subjects depends on the pancreatic glucoregulatory hormones.
Toft-Nielson M; Madsbad S; Holst JJ
Diabetes; 1996 May; 45(5):552-6. PubMed ID: 8621002
[TBL] [Abstract][Full Text] [Related]
9. Inhibition of dipeptidyl peptidase-4 by vildagliptin during glucagon-like Peptide 1 infusion increases liver glucose uptake in the conscious dog.
Edgerton DS; Johnson KM; Neal DW; Scott M; Hobbs CH; Zhang X; Duttaroy A; Cherrington AD
Diabetes; 2009 Jan; 58(1):243-9. PubMed ID: 18840785
[TBL] [Abstract][Full Text] [Related]
10. Effect of intraportal glucagon-like peptide-1 on glucose metabolism in conscious dogs.
Nishizawa M; Moore MC; Shiota M; Gustavson SM; Snead WL; Neal DW; Cherrington AD
Am J Physiol Endocrinol Metab; 2003 May; 284(5):E1027-36. PubMed ID: 12569088
[TBL] [Abstract][Full Text] [Related]
11. Role of glucagon, catecholamines, and growth hormone in human glucose counterregulation. Effects of somatostatin and combined alpha- and beta-adrenergic blockade on plasma glucose recovery and glucose flux rates after insulin-induced hypoglycemia.
Rizza RA; Cryer PE; Gerich JE
J Clin Invest; 1979 Jul; 64(1):62-71. PubMed ID: 36413
[TBL] [Abstract][Full Text] [Related]
12. The glucagon-like peptide-1 metabolite GLP-1-(9-36) amide reduces postprandial glycemia independently of gastric emptying and insulin secretion in humans.
Meier JJ; Gethmann A; Nauck MA; Götze O; Schmitz F; Deacon CF; Gallwitz B; Schmidt WE; Holst JJ
Am J Physiol Endocrinol Metab; 2006 Jun; 290(6):E1118-23. PubMed ID: 16403774
[TBL] [Abstract][Full Text] [Related]
13. Defective amplification of the late phase insulin response to glucose by GIP in obese Type II diabetic patients.
Vilsbøll T; Krarup T; Madsbad S; Holst JJ
Diabetologia; 2002 Aug; 45(8):1111-9. PubMed ID: 12189441
[TBL] [Abstract][Full Text] [Related]
14. Effect of intermittent endogenous hyperglucagonemia on glucose homeostasis in normal and diabetic man.
Rizza R; Verdonk C; Miles J; Service FJ; Gerich J
J Clin Invest; 1979 Jun; 63(6):1119-23. PubMed ID: 447838
[TBL] [Abstract][Full Text] [Related]
15. Blood glucose control in healthy subject and patients receiving intravenous glucose infusion or total parenteral nutrition using glucagon-like peptide 1.
Nauck MA; Walberg J; Vethacke A; El-Ouaghlidi A; Senkal M; Holst JJ; Gallwitz B; Schmidt WE; Schmiegel W
Regul Pept; 2004 Apr; 118(1-2):89-97. PubMed ID: 14759561
[TBL] [Abstract][Full Text] [Related]
16. Effect of glucagon-like peptide-1 (proglucagon 78-107amide) on hepatic glucose production in healthy man.
Hvidberg A; Nielsen MT; Hilsted J; Orskov C; Holst JJ
Metabolism; 1994 Jan; 43(1):104-8. PubMed ID: 8289665
[TBL] [Abstract][Full Text] [Related]
17. Addition of metformin to exogenous glucagon-like peptide-1 results in increased serum glucagon-like peptide-1 concentrations and greater glucose lowering in type 2 diabetes mellitus.
Cuthbertson J; Patterson S; O'Harte FP; Bell PM
Metabolism; 2011 Jan; 60(1):52-6. PubMed ID: 20152998
[TBL] [Abstract][Full Text] [Related]
18. Effects of glucagon-like peptide-I on glucose turnover in rats.
Van Dijk G; Lindskog S; Holst JJ; Steffens AB; Ahrén B
Am J Physiol; 1996 Jun; 270(6 Pt 1):E1015-21. PubMed ID: 8764187
[TBL] [Abstract][Full Text] [Related]
19. Glucagon-like peptide-1 can reverse the age-related decline in glucose tolerance in rats.
Wang Y; Perfetti R; Greig NH; Holloway HW; DeOre KA; Montrose-Rafizadeh C; Elahi D; Egan JM
J Clin Invest; 1997 Jun; 99(12):2883-9. PubMed ID: 9185511
[TBL] [Abstract][Full Text] [Related]
20. Intraportal GLP-1 infusion increases nonhepatic glucose utilization without changing pancreatic hormone levels.
Johnson KM; Edgerton DS; Rodewald T; Scott M; Farmer B; Neal D; Cherrington AD
Am J Physiol Endocrinol Metab; 2007 Oct; 293(4):E1085-91. PubMed ID: 17684104
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
